Scancell Holdings plc, (‘Scancell’ or the ‘Company’) the developer of novel immunotherapies for the treatment of cancer, announces that Dr Richard Goodfellow, Joint CEO of Scancell, is scheduled to present at the 14th Annual Biotech in Europe Forum for Global Partnering and Investment held in Basel, Switzerland on Tuesday 30 September 2014.
Dr Goodfellow will participate in the Oncology II – Next Generation Immunotherapies panel discussion at 2pm where he will be joined by leading cancer experts to discuss the increasing role of combination and targeted therapies.
In a corporate presentation at 4.30pm, Dr Goodfellow will provide an update on the progress of the SCIB1 clinical programme and the development of both the ImmunoBody® and Moditope® platforms.
The Annual Biotech in Europe Forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry and is highly transactional. The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives.
For Further Information:
|Dr Richard Goodfellow, Joint CEO
||Scancell Holdings Plc
||+44 (0) 74 2323 0497
|Professor Lindy Durrant, Joint CEO
||Scancell Holdings Plc
|Mo Noonan/Simon Conway
||+44 (0) 20 3727 1000
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1 has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects.
Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic Tlymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.